SEC Form 4 · accession 0001640455-18-000023
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Murray
Officer — CEO and President · Director
Period of report
Mar 5, 2018
Accepted (ET)
Mar 7, 2018 · 6:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 5, 2018 | M | 16,334 | $0.48 | A | 16,334 | D | |
| Common StockF2 | Mar 5, 2018 | S | 12,100 | $21.21 | D | 4,234 | D | |
| Common StockF3 | Mar 5, 2018 | S | 4,234 | $22.06 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $0.48 | Mar 5, 2018 | M | 16,334 | D | — | Jun 26, 2024 | Common Stock | 16,334 | 873,503 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
- F2Represents the weighted average share price of an aggregate total of 12,100 shares sold in the price range of $20.71 to $21.69 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average share price of an aggregate total of 4,234 shares sold in the price range of $21.82 to $22.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F425% of the option shares vested and became exercisable on July 14, 2015 and the remainder of the option shares vest and become exercisable in 36 monthly installments thereafter.